Physician profile
Michael B Dabrow
NPI 1205806551
$2,545.18
in general payments reported to CMS, 2019-2025
35 companies · $643 in 2025
The $643 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $14.90 · 2021: $20.32 · 2022: $18.56 · 2023: $409 · 2024: $1,224 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $359.60 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $278.35 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $260.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $237.12 | 2023-2025 | Enhertu, Imfinzi |
| Eisai INC. | $138.49 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.52 | 2023-2025 | |
| Glaxosmithkline, LLC. | $96.50 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $80.34 | 2019-2024 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $75.41 | 2023-2024 | Ninlaro, Iclusig, Alunbrig |
| Merck Sharp & Dohme LLC | $74.42 | 2019-2024 | Keytruda, Reblozyl, Welireg |
| Sobi, INC | $64.27 | 2024 | |
| Genmab U.S., INC. | $62.50 | 2024 | Tivdak |
| Daiichi Sankyo INC. | $50.91 | 2025 | Enhertu |
| Alexion Pharmaceuticals, INC. | $49.27 | 2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $48.06 | 2022-2023 | Imbruvica |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $48.05 | 2020-2025 | Erleada |
| Ipsen Biopharmaceuticals, INC | $47.68 | 2025 | Onivyde |
| Tempus Ai, INC | $43.85 | 2024 | |
| Astellas Pharma US INC | $43.41 | 2023-2024 | Xospata |
| Exelixis INC. | $33.92 | 2023-2025 | Cabometyx |
| Incyte Corporation | $32.47 | 2023-2024 | Pemazyre, Monjuvi |
| Abbvie INC. | $32.41 | 2023-2024 | Venclexta |
| Kite Pharma, INC. | $26.86 | 2024 | Yescarta |
| Karyopharm Therapeutics INC. | $26.37 | 2023 | Xpovio |
| Genentech USA, INC. | $25.50 | 2023 | Polivy |
| Aveo Pharmaceuticals, INC. | $24.38 | 2025 | |
| Array Biopharma INC | $23.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.20 | 2025 | Libtayo |
| Lilly USA, LLC | $22.94 | 2019 | |
| G1 Therapeutics, INC. | $22.56 | 2023 | Cosela |
| Seagen INC. | $22.15 | 2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $20.32 | 2021 | |
| Servier Pharmaceuticals LLC | $19.21 | 2024 | |
| Clovis Oncology, INC. | $14.38 | 2019 | |
| Taiho Oncology, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dabrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.